These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36209235)

  • 21. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.
    Bouton TC; Phillips PPJ; Mitnick CD; Peloquin CA; Eisenach K; Patientia RF; Lecca L; Gotuzzo E; Gandhi NR; Butler D; Diacon AH; Martel B; Santillan J; Hunt KR; Vargas D; von Groote-Bidlingmaier F; Seas C; Dianis N; Moreno-Martinez A; Horsburgh CR
    Trials; 2017 Nov; 18(1):563. PubMed ID: 29178937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.
    Maitre T; Bonnet M; Calmy A; Raberahona M; Rakotoarivelo RA; Rakotosamimanana N; Ambrosioni J; Miró JM; Debeaudrap P; Muzoora C; Davis A; Meintjes G; Wasserman S; Wilkinson R; Eholié S; Nogbou FE; Calvo-Cortes MC; Chazallon C; Machault V; Anglaret X; Bonnet F
    Trials; 2022 Nov; 23(1):928. PubMed ID: 36348453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance.
    Park M; Lalvani A; Satta G; Kon OM
    BMC Infect Dis; 2022 Apr; 22(1):349. PubMed ID: 35392842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
    Kwak N; Jeon D; Park Y; Kang YA; Kim KJ; Kim YR; Kwon BS; Kwon YS; Kim HJ; Lee JH; Lee JY; Lee JK; Mok J; Cheon M; Park J; Hahn S; Yim JJ
    Trials; 2022 Aug; 23(1):666. PubMed ID: 35978342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chinese herbal medicine as adjuvant treatment to chemotherapy for multidrug-resistant tuberculosis (MDR-TB): A systematic review of randomised clinical trials.
    Wang M; Guan X; Chi Y; Robinson N; Liu JP
    Tuberculosis (Edinb); 2015 Jul; 95(4):364-72. PubMed ID: 25861717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of integrating traditional care with modern healthcare to improve tuberculosis control programs in Ethiopia: a protocol for a cluster-randomized controlled trial.
    Amare D; Ambaw F; Alene KA
    Trials; 2023 Sep; 24(1):582. PubMed ID: 37697429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial.
    Tadesse AW; Mohammed Z; Foster N; Quaife M; McQuaid CF; Levy J; van Kalmthout K; van Rest J; Jerene D; Abdurhman T; Yazew H; Umeta DG; Assefa D; Weldemichael GT; Bedru A; Letta T; Fielding KL
    BMC Infect Dis; 2021 Nov; 21(1):1149. PubMed ID: 34758737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    Genestet C; Hodille E; Berland JL; Ginevra C; Bryant JE; Ader F; Lina G; Dumitrescu O;
    Int J Antimicrob Agents; 2020 Apr; 55(4):105912. PubMed ID: 31991222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis.
    Drobniewski F; Cooke M; Jordan J; Casali N; Mugwagwa T; Broda A; Townsend C; Sivaramakrishnan A; Green N; Jit M; Lipman M; Lord J; White PJ; Abubakar I
    Health Technol Assess; 2015 May; 19(34):1-188, vii-viii. PubMed ID: 25952553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Directly observed therapy for treating tuberculosis.
    Karumbi J; Garner P
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD003343. PubMed ID: 26022367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial.
    Velen K; Nguyen VN; Nguyen BH; Dang T; Nguyen HA; Vu DH; Do TT; Pham Duc C; Nguyen HL; Pham HT; Marais BJ; Johnston J; Britton W; Beardsley J; Negin J; Wiseman V; Marks GB; Nguyen TA; Fox GJ
    BMJ Open; 2022 Jun; 12(6):e052633. PubMed ID: 35732397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.